Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase NA 3Phase EARLY_PHASE1 2Phase 2 2Phase 4 1Phase 1/2 1

Status

Terminated 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 558Carcinoma, Non-Small-Cell Lung 514Prostatic Neoplasms 336Colorectal Neoplasms 273Neoplasms 269Multiple Myeloma 267Leukemia, Myeloid, Acute 225Squamous Cell Carcinoma of Head and Neck 217Lung Neoplasms 210Neoplasm Metastasis 205Carcinoma, Hepatocellular 198Melanoma 175Triple Negative Breast Neoplasms 174Pancreatic Neoplasms 171Recurrence 153Ovarian Neoplasms 152Lymphoma 142Glioblastoma 136Brain Neoplasms 134Sarcoma 131Carcinoma, Renal Cell 128Lymphoma, Large B-Cell, Diffuse 126Leukemia, Lymphocytic, Chronic, B-Cell 126Head and Neck Neoplasms 124Stomach Neoplasms 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Rectal Neoplasms 109Myelodysplastic Syndromes 104Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

mitazalimab 1Escitalopram 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Ductal Adenocarcinoma × 1 year × Clear all
NCT07199764 2026-03-06

IGNITE

University of Pennsylvania

Phase 2 Recruiting
100 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

NCT05289830 2025-12-10

Escitalopram to Placebo in Patients With Localized Pancreatic Cancer

Case Comprehensive Cancer Center

Phase 2 Terminated
4 enrolled 10 charts
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡